Literature DB >> 23341173

Quality of life of people who inject drugs: characteristics and comparisons with other population samples.

Jane A Fischer1, Sue Conrad, Alexandra M Clavarino, Robert Kemp, Jackob M Najman.   

Abstract

PURPOSE: To assess the quality of life (QOL) of persons who inject drugs.
METHODS: Some 483 current injecting drug users visiting a large NSP over a 2-week period in October 2009 were interviewed using a structured questionnaire. QOL was measured using the WHOQOL-BREF. Data were collected on age, gender, injecting patterns, current drug treatment status and hepatitis C status. Participant QOL profiles were compared to published domain scores for a range of other population groups.
RESULTS: People who inject drugs (PWID) experience a very poor QOL irrespective of socio-demographic characteristics, injecting patterns, hepatitis C sero-status and drug treatment status. Sample participants (PWID) experience a QOL below that experienced by many population groups in the community affected by disabling chronic illnesses.
CONCLUSIONS: Injecting drug use is associated with a poor QOL. Some PWID may be self-medicating for chronic non-malignant pain, and it is likely that these people had a low QOL prior to the decision to inject. Despite this caveat, it remains likely that injecting drug use does little to enhance the QOL of the user.

Entities:  

Mesh:

Year:  2013        PMID: 23341173     DOI: 10.1007/s11136-013-0350-8

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  24 in total

1.  Expecting a good quality of life in health: assessing people with diverse diseases and conditions using the WHOQOL-BREF.

Authors:  Suzanne M Skevington; Farah M McCrate
Journal:  Health Expect       Date:  2011-01-31       Impact factor: 3.377

2.  Using words: the harm reduction conception of drug use and drug users.

Authors:  Nick Stafford
Journal:  Int J Drug Policy       Date:  2007-02-20

3.  A comparison of mood and quality of life among people with progressive neurological illnesses and their caregivers.

Authors:  Marita P McCabe; Lucy Firth; Elodie O'Connor
Journal:  J Clin Psychol Med Settings       Date:  2009-07-29

4.  Quality of life and mental illness. Reflections from the perspective of the WHOQOL.

Authors:  J Orley; S Saxena; H Herrman
Journal:  Br J Psychiatry       Date:  1998-04       Impact factor: 9.319

5.  Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group.

Authors: 
Journal:  Psychol Med       Date:  1998-05       Impact factor: 7.723

6.  The relationship between personality disorders and mental health, substance use severity and quality of life among injecting drug users.

Authors:  Tania M Gibbie; Leanne M Hides; Sue M Cotton; Daniel I Lubman; Campbell Aitken; Margaret Hellard
Journal:  Med J Aust       Date:  2011-08-01       Impact factor: 7.738

Review 7.  Quality of life in alcohol-dependent subjects--a review.

Authors:  J H Foster; J E Powell; E J Marshall; T J Peters
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

8.  Internal consistency and validity of the Stroke Impact Scale 2.0 (SIS 2.0) and SIS-16 in an Australian sample.

Authors:  Ben Edwards; Bev O'Connell
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

9.  Is there a measurement overlap between depressive symptoms and quality of life?

Authors:  Neusa Sica da Rocha; Mick J Power; Donald M Bushnell; Marcelo P Fleck
Journal:  Compr Psychiatry       Date:  2009-03-10       Impact factor: 3.735

10.  Patterns of ecstasy use in Australia: findings from a national household survey.

Authors:  Louisa Degenhardt; Bridget Barker; Libby Topp
Journal:  Addiction       Date:  2004-02       Impact factor: 6.526

View more
  9 in total

1.  Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results.

Authors:  Ru Han; Clément François; Mondher Toumi
Journal:  Appl Health Econ Health Policy       Date:  2021-01       Impact factor: 2.561

2.  Survival and Health-Related Quality of Life after Hospitalization for Necrotizing Soft Tissue Infections of the Upper Extremity: A Long-Term Outcome Study.

Authors:  Femke Nawijn; Svenna H W L Verhiel; Juliette Nierich; Kyle R Eberlin; Falco Hietbrink; Neal C Chen
Journal:  J Hand Microsurg       Date:  2020-05-06

3.  High prevalence of HIV, HCV and tuberculosis and associated risk behaviours among new entrants of methadone maintenance treatment clinics in Guangdong Province, China.

Authors:  Lei Zhang; Di Zhang; Wen Chen; Xia Zou; Li Ling
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

4.  Performance of the WHOQOL-BREF among Norwegian substance use disorder patients.

Authors:  Ashley Elizabeth Muller; Svetlana Skurtveit; Thomas Clausen
Journal:  BMC Med Res Methodol       Date:  2019-03-04       Impact factor: 4.615

5.  Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach.

Authors:  Ru Han; Shuyao Liang; Clément François; Samuel Aballea; Emilie Clay; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2021-03-25

6.  The Impact of Qigong and Tai Chi Exercise on Drug Addiction: A Systematic Review and Meta-Analysis.

Authors:  Jiabao Cui; Fang Liu; Xuan Liu; Ru Li; Xiaorong Chen; Hongfa Zeng
Journal:  Front Psychiatry       Date:  2022-03-08       Impact factor: 4.157

7.  Changes in clients' well-being (ORS) and state hope (SHS) during inpatient substance abuse treatment.

Authors:  Eeva Ekqvist; Katja Kuusisto
Journal:  Nordisk Alkohol Nark       Date:  2020-06-05

8.  Perceived quality of life, 6 months after detoxification: Is abstinence a modifying factor?

Authors:  John-Kåre Vederhus; Bente Birkeland; Thomas Clausen
Journal:  Qual Life Res       Date:  2016-03-19       Impact factor: 4.147

9.  Longitudinal changes in personal wellbeing in a cohort of people who inject drugs.

Authors:  Nick Scott; Elise R Carrotte; Peter Higgs; Mark A Stoové; Campbell K Aitken; Paul M Dietze
Journal:  PLoS One       Date:  2017-05-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.